MAP2K1 and cancer: We have found that refametinib, an extensively studied allosteric MEK1/2 inhibitor, which has undergone extensive preclinical and clinical evaluation in multiple cancer subtypes, has sensitivity in HER2-positive breast cancer cell lines.